Microglial activation is raised in preclinical Alzheimer’s disease and associated with covert memory impairment

Read full text
Authors: Pernille Louise Kjeldsen, Lasse Stensvig Madsen, Peter Parbo, Rola Ismail, Joel Fredrik Astrup Aanerud, Malene Kaasing, Malene Flensborg Damholdt, Simon Fristed Eskildsen, Leif Østergaard, David J. Brooks
Cited by: 2
References: 54

Abstract

Background Alzheimer’s disease (AD) is a continuum between normal health and dementia with a long preclinical phase, during which AD pathologies start to emerge, but where there are not yet any overt symptoms. The hallmark pathologies of AD are extracellular β -amyloid (Aβ) plaques and intra-neuronal neurofibrillary tangles (NFTs). Aβ deposition is present at the preclinical stage. Additionally, raised microglial activation is a key factor in AD. However, its exact timing and role is still unclear. This exploratory study investigated the prevalence of microglial activation and its association with Aβ deposition and memory impairment in preclinical AD. Methods A total of 19 preclinical AD subjects with no cognitive complaints but abnormal Aβ deposition present on 11 C-Pittsburgh Compound B ( 11 C-PiB PET) and 10 healthy subjects with no cognitive complains or abnormal Aβ deposition on 11 C-PiB PET underwent 11 C-PK11195 PET ( 11 C-PK). Additionally, the preclinical AD subjects underwent formal cognitive testing with sensitive memory tests, including the Rey Auditory Verbal Learning Test, the Rey Complex Figure Test, and the Face-Name Associative Memory Exam. Results Microglial activation was raised in occipital and parietal cortices in preclinical AD subjects compared to healthy controls ( p < 0.01). In the preclinical subjects there were significant positive correlations between Aβ load and microglial activation in parietal areas ( p < 0.01). Finally, in the preclinical subjects, there were significant negative correlations between microglial activation and memory test performance in selected cortical areas ( p < 0.01). Conclusion Microglial activation was significantly raised in preclinical AD cases with no cognitive complaints and associated with impaired memory test performance. This suggests that microglial activation is present before overt clinical symptoms emerge and may be detrimental to cognition even at this early stage.

Fields of Study & Subjects

Alzheimer's disease research and treatments Neuroinflammation and Neurodegeneration Mechanisms Dementia and Cognitive Impairment Research

Publication details

Journal / source
Frontiers in Dementia
Publisher
Frontiers Media SA
Volume
4
Pages
1745571–1745571
Publication date
27 January 2026
Language
EN